{"protocolSection": {"identificationModule": {"nctId": "NCT00701090", "orgStudyIdInfo": {"id": "0431-803"}, "secondaryIdInfos": [{"id": "2008_503"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)", "officialTitle": "A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-05"}, "primaryCompletionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-17", "studyFirstSubmitQcDate": "2008-06-18", "studyFirstPostDateStruct": {"date": "2008-06-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-09-13", "resultsFirstSubmitQcDate": "2010-09-13", "resultsFirstPostDateStruct": {"date": "2010-10-05", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-30", "lastUpdatePostDateStruct": {"date": "2017-03-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride. This study will also see if this treatment is safe and tolerable."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus, Non Insulin Dependent", "Diabetes Mellitus, Non-Insulin-Dependent"], "keywords": ["Type 2 Diabetes Mellitus", "Non Insulin Dependent"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1035, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "sitagliptin", "interventionNames": ["Drug: sitagliptin", "Drug: open-label metformin"]}, {"label": "2", "type": "ACTIVE_COMPARATOR", "description": "glimepiride", "interventionNames": ["Drug: Comparator: glimepiride", "Drug: open-label metformin"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin", "description": "Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks", "armGroupLabels": ["1"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "Comparator: glimepiride", "description": "glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "open-label metformin", "description": "open-label metformin oral tablets (\u22651500 mg/day) in addition to Glimepiride or Sitagliptin treatment.", "armGroupLabels": ["1", "2"], "otherNames": ["metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in HbA1c at Week 30", "description": "Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.", "timeFrame": "Week 0 to Week 30"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30", "description": "Change from baseline at Week 30 was defined as Week 30 minus Week 0.", "timeFrame": "Week 0 to Week 30"}, {"measure": "Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30", "timeFrame": "Week 0 to Week 30"}, {"measure": "Change From Baseline in Body Weight at Week 30", "description": "Change from baseline at Week 30 was defined as Week 30 minus Week 0.", "timeFrame": "Week 0 to Week 30"}, {"measure": "Percent of Patients With A1C <7.0% at Week 30", "timeFrame": "Week 30"}, {"measure": "Percent of Patients With A1C <6.5% at Week 30", "timeFrame": "Week 30"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with type 2 diabetes\n* On a stable dose of metformin of at least 1500 mg per day\n\nExclusion Criteria:\n\n* History of type 1 diabetes\n* Pregnant\n* HIV positive\n* On a weight loss program or medication\n* Has a history of blood disorder, certain cancers, heart, liver or kidney disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "21199268", "type": "RESULT", "citation": "Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011 Feb;13(2):160-8. doi: 10.1111/j.1463-1326.2010.01334.x."}, {"pmid": "25633134", "type": "DERIVED", "citation": "Ommen ES, Xu L, O'Neill EA, Goldstein BJ, Kaufman KD, Engel SS. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials. Diabetes Ther. 2015 Mar;6(1):29-40. doi: 10.1007/s13300-015-0098-y. Epub 2015 Jan 30. Erratum In: Diabetes Ther. 2015 Mar;6(1):97-8."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf\n\nhttp://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients at least 18 years of age with type 2 diabetes mellitus with inadequate glycemic control (A1C \u22656.5 and \u22649.0%) on a stable dose of metformin (at a dose of at least 1500 mg per day for at least 12 weeks) were eligible to enter the 30 week study. Up to a 2 week screening period, followed by a 2-week placebo run-in.", "recruitmentDetails": "Phase III\n\nFirst Patient In: 14-May-2008; Last Patient Last Visit: 27-Oct-2009; 109 study centers worldwide", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "FG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "516"}, {"groupId": "FG001", "numSubjects": "519"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "468"}, {"groupId": "FG001", "numSubjects": "468"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "51"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "12"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "BG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "516"}, {"groupId": "BG001", "value": "519"}, {"groupId": "BG002", "value": "1035"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.3", "spread": "9.7"}, {"groupId": "BG001", "value": "56.2", "spread": "10.1"}, {"groupId": "BG002", "value": "56.3", "spread": "9.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "232"}, {"groupId": "BG001", "value": "240"}, {"groupId": "BG002", "value": "472"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "284"}, {"groupId": "BG001", "value": "279"}, {"groupId": "BG002", "value": "563"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "297"}, {"groupId": "BG001", "value": "298"}, {"groupId": "BG002", "value": "595"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "111"}, {"groupId": "BG002", "value": "220"}]}]}, {"title": "American Indian/Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "51"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "157"}]}]}]}, {"title": "A1C (Hemoglobin A1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.50", "spread": "0.70"}, {"groupId": "BG001", "value": "7.51", "spread": "0.76"}, {"groupId": "BG002", "value": "7.50", "spread": "0.73"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in HbA1c at Week 30", "description": "Patient-level HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 30 HbA1c percent minus the Week 0 HbA1c percent.", "populationDescription": "The per protocol population included all patients with a baseline value, a measurement at Week 30, and no major protocol violations (i.e., drug compliance \\<85%, use of prohibited medications, change of Metformin dose, incorrect double-blind study medication).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Week 0 to Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "443"}, {"groupId": "OG001", "value": "436"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.47", "lowerLimit": "-0.55", "upperLimit": "-0.39"}, {"groupId": "OG001", "value": "-0.54", "lowerLimit": "-0.62", "upperLimit": "-0.45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The pre-specified non-inferiority margin was 0.4%, i.e., Sitagliptin was declared non-inferior to glimepiride if the upper limit of the two-sided 95% confidence interval for the between group difference (sitagliptin minus glimepiride) was less than 0.4%", "paramType": "Mean Difference (Net)", "paramValue": "0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.16", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "0.70", "estimateComment": "ANCOVA model with terms: treatment, country, and baseline HbA1c."}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG (Fasting Plasma Glucose) at Week 30", "description": "Change from baseline at Week 30 was defined as Week 30 minus Week 0.", "populationDescription": "The per protocol population included all patients with a baseline value, a measurement at Week 30, and no major protocol violations (i.e., drug compliance \\<85%, use of prohibited medications, change of Metformin dose, incorrect double-blind study medication).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Week 0 to Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "446"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-14.6", "lowerLimit": "-17.9", "upperLimit": "-11.2"}, {"groupId": "OG001", "value": "-17.5", "lowerLimit": "-20.8", "upperLimit": "-14.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "2.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.9", "ciUpperLimit": "6.7", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "28.8", "estimateComment": "ANCOVA model terms: treatment, country, and baseline."}]}, {"type": "SECONDARY", "title": "Percent of Patients With at Least One Hypoglycemia Episode of Any Type at Week 30", "populationDescription": "All patients who took at least one dose of study therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 0 to Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "516"}, {"groupId": "OG001", "value": "518"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.0"}, {"groupId": "OG001", "value": "22.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Miettinen &Nurminen method", "paramType": "Risk Difference (RD)", "paramValue": "-15.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-19.3", "ciUpperLimit": "-10.9", "estimateComment": "Miettinen \\&Nurminen method was used for the 95% confidence interval"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 30", "description": "Change from baseline at Week 30 was defined as Week 30 minus Week 0.", "populationDescription": "All patients who took at least one dose of study therapy and had body weight measurements at both baseline and Week 30.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Week 0 to Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "465"}, {"groupId": "OG001", "value": "461"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "lowerLimit": "-1.1", "upperLimit": "-0.5"}, {"groupId": "OG001", "value": "1.2", "lowerLimit": "0.9", "upperLimit": "1.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment, country, and baseline.", "paramType": "Mean Difference (Net)", "paramValue": "-2.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.3", "ciUpperLimit": "-1.6", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "2.9", "estimateComment": "ANCOVA model terms: treatment, country, and baseline."}]}, {"type": "SECONDARY", "title": "Percent of Patients With A1C <7.0% at Week 30", "populationDescription": "The per protocol population included all patients with a baseline value, a measurement at Week 30, and no major protocol violations (i.e., drug compliance \\<85%, use of prohibited medications, change of Metformin dose, incorrect double-blind study medication).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "443"}, {"groupId": "OG001", "value": "436"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.4"}, {"groupId": "OG001", "value": "59.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Odds Ratio (OR)", "paramValue": "0.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.47", "ciUpperLimit": "0.90", "estimateComment": "The parameter estimate and 95% CI represent the odds of having A1C \\<7.0% at Week 30 in the Sitagliptin group vs. the Glimepiride group, computed using a logistic regression model controlling for treatment, country and baseline A1C."}]}, {"type": "SECONDARY", "title": "Percent of Patients With A1C <6.5% at Week 30", "populationDescription": "The per protocol population included all patients with a baseline value, a measurement at Week 30, and no major protocol violations (i.e., drug compliance \\<85%, use of prohibited medications, change of Metformin dose, incorrect double-blind study medication).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}, {"id": "OG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "443"}, {"groupId": "OG001", "value": "436"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.2"}, {"groupId": "OG001", "value": "27.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Odds Ratio (OR)", "paramValue": "0.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.47", "ciUpperLimit": "0.95", "estimateComment": "The parameter estimate and 95% CI represent the odds of having A1C \\<6.5% at Week 30 in the Sitagliptin group vs. the Glimepiride group, computed using a logistic regression model controlling for treatment, country and baseline A1C."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Particpants analyzed are those who received at least 1 dose of study medication. One participant in the Glimepiride group did not receive any study medication and is not included in the analysis.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "The Sitagliptin 100 mg q.d. (q.d. = once daily) group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily (blinded) in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day).", "seriousNumAffected": 16, "seriousNumAtRisk": 516, "otherNumAffected": 58, "otherNumAtRisk": 519}, {"id": "EG001", "title": "Glimepiride", "description": "The Glimepiride group includes data from patients randomized to receive treatment starting with 1 mg oral tablets of glimepiride (blinded) up-titrated until Week 18 as needed to a maximum dose of 6 mg q.d. in addition to ongoing treatment with open-label metformin oral tablets (\u22651500 mg/day).", "seriousNumAffected": 11, "seriousNumAtRisk": 518, "otherNumAffected": 134, "otherNumAtRisk": 518}], "seriousEvents": [{"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Mastitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Peritonsillar abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Typhoid fever", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Clavicle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Lung squamous cell carcinoma stage unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Autonomic neuropathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 518}]}, {"term": "Prostatitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 516}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 518}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 519}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 518}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (12.1)", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 519}, {"groupId": "EG001", "numAffected": 114, "numAtRisk": 518}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Austria", "Brazil", "Chile", "Colombia", "Costa Rica", "Denmark", "Ecuador", "France", "Germany", "Guatemala", "India", "Italy", "Korea, Republic of", "Malaysia", "Mexico", "New Zealand", "Panama", "Peru", "Poland", "Spain", "Switzerland", "United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Non-Insulin-Dependent", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}